NR3C2 and hypertensive disorder: For example, mineralocorticoid receptor antagonists were used in 22–28% of patients in the SYMPLICITY HTN-3 trial, 17% in the SYMPLICITY HTN-2 trial, and 37–45% of patients in the SYMPLICITY HTN-Japan trial.